Charlottes Web Holdingsの空売り状況は、投資家がCharlottes Web Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Charlottes Web Holdings (OTC:CWBHF) 株価情報, 空売り情報

Charlottes Web Holdings

Charlottes Web Holdings Inc is engaged in the production and distribution of hemp-based cannabidiol (CBD) wellness products. Its product categories include ingestible products (tinctures, capsules, and gummies), topicals, and pet products. The company distributes its products through an e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers.

CHARLOTTES WEB HLDGS INC by Charlotte's Web Holdings Inc.

Charlottes Web Holdings Inc

Morningstar's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NYSE">MORN</a>) short percent of float has fallen 7.43% since its last report. The company recently reported that it has 510 thousand shares sold short, which is 1.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Morningstar Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750424428_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Morningstar has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Morningstar's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Morningstar's peer group average for short interest as a percentage of float is 5.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

MORN

How Is The Market Feeling About Morningstar?

News

Politics

General

iShares MSCI Israel Capped Investable Market Index Fund

Reuters Reports Israeli Media Says Initial Reports Indicate Missile Impacts In Tel Aviv, The Negev And Haifa

Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Builders FirstSource, presenting an average target of $141.46, a high estimate of $170.00, and a low estimate of $118.00. This current average represents a 11.22% decrease from the previous average price target of $159.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1750424426_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Builders FirstSource is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$118.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Trey Grooms</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Sam Darkatsh</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$137.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Jeffrey Stevenson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$151.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Collin Verron</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$151.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Builders FirstSource. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Builders FirstSource compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Builders FirstSource's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Builders FirstSource's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BLDR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Builders FirstSource analyst ratings.</a>
<h2>Get to Know Builders FirstSource Better</h2>
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
<h3>Builders FirstSource: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Builders FirstSource's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -6.01% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Builders FirstSource's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.22%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Builders FirstSource's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.87%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.17, Builders FirstSource faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BLDR

Breaking Down Builders FirstSource: 13 Analysts Share Their Views

Teradyne's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TER#NYSE">TER</a>) short percent of float has fallen 11.33% since its last report. The company recently reported that it has 6.35 million shares sold short, which is 4.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teradyne Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750424423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teradyne has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teradyne's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teradyne's peer group average for short interest as a percentage of float is 9.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Teradyne?

MARA Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NYSE">MARA</a>) short percent of float has fallen 7.72% since its last report. The company recently reported that it has 87.53 million shares sold short, which is 32.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>MARA Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750424418_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MARA Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MARA Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, MARA Holdings's peer group average for short interest as a percentage of float is 8.97%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MARA

Looking Into MARA Holdings's Recent Short Interest

Analysts' ratings for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) over the last quarter vary from bullish to bearish, as provided by 32 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">23</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">18</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $439.91, a high estimate of $660.00, and a low estimate of $270.00. This current average has decreased by 21.39% from the previous average price target of $559.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1750424417_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive UnitedHealth Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$418.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$312.00</td>
<td>$356.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$353.00</td>
<td>$552.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Sidharth Sahoo</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$270.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Justin Lake</td>
<td>Wolfe Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$501.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$308.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$360.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$362.00</td>
<td>$513.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$362.00</td>
<td>$521.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$351.00</td>
<td>$677.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$374.00</td>
<td>$563.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$356.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$510.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$513.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$525.00</td>
<td>$652.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$525.00</td>
<td>$655.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$563.00</td>
<td>$664.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$580.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$560.00</td>
<td>$642.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$540.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$660.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$650.00</td>
<td>$600.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to UnitedHealth Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UnitedHealth Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for UnitedHealth Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into UnitedHealth Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UNH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on UnitedHealth Group analyst ratings.</a>
<h2>Delving into UnitedHealth Group's Background</h2>
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>UnitedHealth Group's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: UnitedHealth Group's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 9.8%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: UnitedHealth Group's net margin is impressive, surpassing industry averages. With a net margin of 5.74%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.7%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): UnitedHealth Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.07% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.86, UnitedHealth Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For UnitedHealth Group's Future

Wedbush analyst Daniel Ives reiterates NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Outperform and maintains $200 price target.

Price Target

Reiteration

NICE

Wedbush Reiterates Outperform on NICE, Maintains $200 Price Target

Commercial Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) will release its third-quarter earnings results before the <a href="https://www.benzinga.com/quote/CMC/earnings">opening bell on Monday, June 23.</a>
Analysts expect the company to report quarterly earnings at 84 cents per share, down from $1.02 per share in the year-ago period. Commercial Metals is projected to report quarterly revenue of $2.04 billion, compared to $2.08 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 20, Commercial Metals reported second-quarter 2025 results, with net sales down 5.1% year-over-year to $1.754 billion, broadly in line with the analyst expectations of $1.746 billion.
With the recent buzz around Commercial Metals, some investors may be eyeing potential gains from the company's dividends too. As of now, Commercial Metals offers an annual dividend yield of 1.47%, which is a quarterly dividend amount of 18 cents per share (72 cents a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $408,650 or around 8,333 shares. For a more modest $100 per month or $1,200 per year, you would need $81,750 or around 1,667 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.72 in this case). So, $6,000 / $0.72 = 8,333 ($500 per month), and $1,200 / $0.72 = 1,667 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
CMC Price Action: Shares of Commercial Metals rose 0.2% to close at $49.04 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

Dividends

Markets

How To Earn $500 A Month From Commercial Metals Stock Ahead Of Q3 Earnings

Wells Fargo analyst Praneeth Satish maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Overweight and lowers the price target from $65 to $42.

ENPH

Wells Fargo Maintains Overweight on Enphase Energy, Lowers Price Target to $42

WIIM

AIFF

Firefly Neuroscience shares are trading higher after the company. announced a breakthrough in Alzheimer's detection using combined EEG/ERP and vMRI.

Wells Fargo analyst Michael Blum maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Equal-Weight and raises the price target from $7 to $8.

ARRY

Wells Fargo Maintains Equal-Weight on Array Technologies, Raises Price Target to $8

XXII

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

UNCY

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Outperform and maintains $36 price target.

KURA

Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

Investor optimism surrounding a potential XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) exchange-traded fund (ETF) has <a href="https://www.benzinga.com/etfs">reached new heights</a>. 
What Happened: Bettors on the Polymarket prediction platform are assigning an 89% chance of U.S. approval for XRP ETF by the end of 2025.
This surge in confidence, up from 70% earlier this year, reflects growing expectations that XRP could soon join Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) in the ETF arena, potentially reshaping the altcoin market. 
Trading activity on Polymarket has also intensified, with volumes <a href="https://polymarket.com/event/ripple-etf-approved-in-2025?tid=1750364809325">exceeding </a>$95,000, signaling strong market interest driven by regulatory developments and insider sentiment.
An XRP ETF would allow investors to gain exposure to the cryptocurrency through traditional stock exchanges, eliminating the need for managing digital wallets. 
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46016990/apple-google-and-facebook-among-services-exposed-in-massive-leak-of-more-than-16-billion-login-records">Apple, Google and Facebook Among Services Exposed In Massive Leak of More Than 16 Billion Login Records</a>
Why It Matters: If approved, an XRP ETF could serve as a pivotal moment for Ripple — the company that created it — and pave the way for greater institutional adoption.
For traders, anticipating ETF approval will likely fuel volatility, creating opportunities for significant price movements as the decision deadline nears.
However, the U.S. Securities and Exchange Commission (SEC) delayed its decision on Franklin Templeton's proposed spot XRP ETF by 35 days. Instead, it opted to open a public comment period.
This delay also affects Franklin Templeton's proposed spot Solana ETF. 
Despite the postponement, 3iQ XRP ETF was launched on the Toronto Stock Exchange on June 18 this year.
The rising odds of U.S. approval highlight a broader trend of cryptocurrencies transitioning into regulated investment vehicles. 
Bitwise and Grayscale have also filed for XRP-related investment products. No approvals have been granted in the U.S. as yet.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46016723/mantles-tim-chen-explains-why-layer-2-ecosystems-are-critical-despite-retail-hesitation">Mantle&#8217;s Tim Chen Explains Why Layer 2 Ecosystems Are Critical Despite Retail Hesitation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Why XRP Could Be The Next Big ETF Bet And What Polymarket Traders Know That You Don't

Wedbush analyst Matt Bryson initiates coverage on NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Outperform rating and announces Price Target of $35.

Initiation

NATL

Wedbush Initiates Coverage On NCR Atleos with Outperform Rating, Announces Price Target of $35

<a href="https://www.globenewswire.com/Tracker?data=HMXwERE9PQskd73yKQRzMih2mDrTOTJc3AP_16WsqAFlMeJPPFgyAIBJX3VCN6_ztabx0RwDCPeoQVGtJtkOgq661KIk8QWPirFVAzu8o1hBSJH97uk1KOiYQIFgKlVKbEaDlFhV_XxCvAnkRvuaPkbNTlqegEvedh44GQ7FCyMWwqmv-bgTkc4JL2u14Snrub3Zv4007KtxIVphj9xMKg==">The poster</a> described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment.

Biotech

ACTU

Actuate Therapeutics Highlights Biomarker, Machine Learning Data From Phase 2 Elraglusib Trial In First-Line Treatment Of  Metastatic Pancreatic Cancer

Wedbush analyst Daniel Ives reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and maintains $500 price target.

TSLA

Wedbush Reiterates Outperform on Tesla, Maintains $500 Price Target

You don't need to make reckless bets in the stock market or fall for scammy investment schemes to lose money. Sometimes, the biggest threats to your financial future are the quiet, unassuming habits that slowly drain your wealth in the background. They rarely make headlines, and they don't feel dramatic in the moment—but over time, they quietly erode your ability to build lasting security. These are the seven silent wealth drains that might already be working against you—and what to do about each one before they permanently set you back.
<h2 class="wp-block-heading">1. Lifestyle Creep</h2>
This one happens slowly, almost invisibly. You get a raise, and suddenly your $2,000 vacation becomes a $6,000 luxury escape. The sensible car you were perfectly happy with now feels "beneath you," and it gets swapped out for something flashier. The takeout orders increase, the impulse Amazon purchases multiply, and the monthly bills balloon—not because you needed more, but because you could afford more.
The problem? Every time your income rises and your spending rises with it, you&#8217;re robbing your future self of the opportunity to build wealth. That extra $10,000 a year could have gone into your IRA, into real estate, into a brokerage account compounding quietly for the next 30 years. Instead, it gets absorbed into an upgraded lifestyle that feels normal almost immediately—and hard to scale back.
The fix isn't deprivation—it's discipline. Lock in your lifestyle before the raise. If you get a $10,000 raise, try saving or investing at least $5,000 of it before you touch the rest. Future-you will thank you.
Related:
<ul class="wp-block-list">
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
<li>Put your money to work for you: In terms of getting money back, <a href="https://www.gobankingrates.com/best-banks-c/">these bank accounts put traditional checking and savings accounts to shame</a>.</li>
</ul>
<h2 class="wp-block-heading">2. Subscription Sprawl</h2>
You probably don't even know how many subscriptions you're currently paying for. Between streaming services, news sites, productivity apps, forgotten software trials, and gym memberships that seemed like a good idea in January, these recurring charges are the financial equivalent of death by a thousand cuts. $9.99 here, $14.99 there—individually, they're harmless. Collectively, they're often hundreds, sometimes thousands of dollars a year.
What makes this so dangerous is how invisible it is. These aren't big, emotional purchases you consciously weigh—they're quiet, autopilot charges that keep hitting your credit card month after month. And every dollar wasted on a forgotten subscription is a dollar not earning compound returns somewhere else.
The solution? Set a calendar reminder every 3–6 months to audit your subscriptions. Open your bank and credit card statements, sort by recurring charges, and get ruthless. If it doesn't spark value, cut it. Let "set it and forget it" become "set it and review it."
<h2 class="wp-block-heading">3. High-Interest Debt</h2>
Credit card balances. Buy-now-pay-later loans. Personal loans with double-digit interest rates. These might feel manageable—just $3,000 or $4,000 spread across a couple of cards—but they're often doing more financial damage than you realize. With interest rates of 20% or more, even a modest balance can snowball into a mountain of debt that's hard to escape.
Here's the math: if you&#8217;re making the minimum payment on a $5,000 credit card at 20% interest, it can take over a decade to pay it off—and you'll likely pay more than double in total. That's money that could've been earning for you instead of bleeding out to lenders.
Before you even think about investing, attack your high-interest debt with laser focus. Every dollar you put toward it gives you a "return" equal to the interest rate you&#8217;re avoiding. Once it's paid off, redirect those payments toward long-term savings and investments.
<h2 class="wp-block-heading">4. Idle Cash</h2>
There's nothing wrong with keeping cash on hand—but too much of it sitting in the wrong place is quietly working against you. If you've got thousands languishing in a checking account earning 0.01% interest—or worse, under your mattress—it's not just doing nothing. It's actively losing value to inflation.
Inflation doesn't feel like a bill, but it functions like one. If inflation runs at 3% and your cash is earning 0.01%, your purchasing power is shrinking year after year. That emergency fund that felt solid five years ago may no longer cover the same expenses today.
A better approach is to segment your cash. Keep 3–6 months of essential expenses in a high-yield savings account or money market fund—somewhere safe, but with a real return. Everything beyond that should be working harder for you: invested in diversified assets that historically outpace inflation and help your money grow.
<h2 class="wp-block-heading">5. Fees You Don't See</h2>
You probably wouldn't knowingly pay $10,000 a year to someone just to manage your investments—but many people do exactly that without realizing it. Hidden fees in mutual funds, advisory charges, transaction costs, and seemingly harmless 1% management fees can quietly siphon six figures from your portfolio over time.
Let's break it down. A 1% annual fee on a $500,000 portfolio is $5,000 per year. Over 30 years, with compounding lost, that can easily cost you over $150,000. That's not pocket change—that's retirement years shaved off the back end.
What can you do? Start by getting clarity. Ask your advisor to spell out all fees in plain English. Use low-cost index funds or ETFs where possible, and favor platforms that minimize transaction and management fees. A few percentage points saved here and there can add up to serious money decades down the line.
Trending: 
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/cancervax-advertorial-y2">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/mode-mobile-accredited-investor-y2">invest with $1,000 at just $0.30/share.</a></li>
</ul>
<h2 class="wp-block-heading">6. Delayed Investing</h2>
There's always a reason to wait. The market feels uncertain. You don't have enough saved. You're still learning. But while you're on the sidelines, time keeps ticking—and that's the one resource you can't get back.
The reality is this: the earlier you start, the less you have to invest to reach the same goal. That's the magic of compounding. Delay by five years, and you may need to double your monthly contributions just to catch up. And let's be honest—no one ever feels fully "ready" to invest. There will always be a new headline, a looming recession, or a market dip to worry about.
Start small. Automate contributions. Let the habit build. Because in investing, time in the market always beats timing the market.
<h2 class="wp-block-heading">7. Ignoring Inflation</h2>
You might not see it, but inflation is constantly nibbling away at your purchasing power. The $1,000 you tuck under your mattress today will not buy $1,000 worth of goods a decade from now. Over 20–30 years, that erosion becomes dramatic—especially when you&#8217;re planning for retirement or other long-term goals.
A gallon of milk, a tank of gas, a doctor's visit—these things will cost more in the future. If your money isn't growing at least as fast as inflation, you're falling behind even if your balance stays the same.
The fix is planning with inflation in mind. Don't just look at nominal dollars—think about what those dollars will actually buy in the future. Prioritize investments like stocks, real estate, and Treasury Inflation-Protected Securities (TIPS) that tend to outpace inflation over time. Safe doesn't always mean smart when it comes to long-term wealth.
<h2 class="wp-block-heading">The Takeaway</h2>
You don't have to blow your money to lose it. These silent wealth drains work quietly, month after month, year after year. They don't grab your attention like a bad stock pick or a big splurge, but they do just as much damage—if not more—because they often go unnoticed until it's too late.
Wealth isn't just about what you earn—it's about what you keep, what you grow, and what you don't leak out the sides. Fixing these issues doesn't require genius or a windfall. It just takes awareness, a little strategy, and a willingness to plug the holes early.
Clean up the leaks. Redirect those dollars toward your future. Let your money do what it was always meant to do: build a life that feels free, secure, and fully yours.
See Next: 
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=jeffbezos100"> Here&#8217;s how you can earn passive income with just $100.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=532&amp;aff_id=1">you can become an investor for $0.80 per share today.</a></li>
</ul>
<h2 class="wp-block-heading">Want a Second Opinion on Your Finances?</h2>
If you're serious about plugging the leaks and building a more intentional financial future, <a href="https://www.rm2djk4ss.com/BW4BPX/J8P3N/">Wiser Advisor can help</a>. Its platform connects you with experienced, vetted fiduciary advisors who can break down your money situation, uncover the quiet drains you might be missing, and map out a smarter path forward for free.

Personal Finance

7 Silent Wealth Drains That Are Sabotaging Your Future

A popular crypto trader is raising concerns about the price stability of Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>), a popular meme coin rivaling Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>). 
The trader, known online as Altcoin Sherpa, <a href="https://x.com/AltcoinSherpa/status/1935699918649536605">shared </a>with his 248,000+ followers on X (formerly Twitter) that WIF must maintain a key support level of $0.78 or risk entering a prolonged downward trend.
"WIF needs to hold these levels or a broader decline may follow for similar tokens," he wrote, suggesting that many lower-timeframe charts already show bearish structures.
WIF is currently trading at $0.8001, up about 0.5% over the past 24 hours.
In a separate observation, Sherpa <a href="https://x.com/AltcoinSherpa/status/1935687524313391241">shared </a>a technical chart indicating that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) could be preparing for a breakout toward an all-time high near $124,000. 
Despite prevailing economic uncertainty, he remains optimistic.
He pointed to ongoing geopolitical tensions and the lack of interest rate cuts, yet noted, "BTC is still above $100,000? That's bullish."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46016723/mantles-tim-chen-explains-why-layer-2-ecosystems-are-critical-despite-retail-hesitation">Mantle&#8217;s Tim Chen Explains Why Layer 2 Ecosystems Are Critical Despite Retail Hesitation</a>
Still, he urged caution. 
A surprise event or unfavorable news could trigger a sharp drop below $100,000, he said. "I'm not jumping into many trades at the moment. I'm fine holding some losing positions for now. Better to be patient and use this time for research."
At the time of writing, Bitcoin was priced at $105,980, up about 1% for the day.
The trader also <a href="https://x.com/AltcoinSherpa/status/1935665703362932742">commented </a>on Hyperliquid (CRYPTO: HYPE), a newer layer-1 blockchain project. According to his analysis, the token may revisit support around $31.84 if Bitcoin experiences further volatility.
"HYPE might dip into the low $30s if BTC continues to trade sideways or declines. Still, it's one of the stronger performers this cycle, and I'm holding my staked position," he wrote.
HYPE was trading at $37.2 at the time of reporting, down over 3% in the past 24 hours.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46016990/apple-google-and-facebook-among-services-exposed-in-massive-leak-of-more-than-16-billion-login-records">Apple, Google and Facebook Among Services Exposed In Massive Leak of More Than 16 Billion Login Records</a></li>
</ul>
Photo: Shutterstock

$DOGE

$WIF

Trader Warns Dogwifhat Could Trigger Meme Coin Meltdown If Key Level Breaks

Press Releases

DeFloria Announces Positive Results from Phase 1 Trial of AJA001 Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

Small Cap

Charlotte's Web Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder

DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

Comments

Charlottes Web Holdings

空売り

Charlottes Web Holdings (OTC:CWBHF) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル